Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8266044 | 0.81 | HPGD (0.48) | MAPTTDP1CYP1A2CYP3A4LMNA | |
| SCHEMBL4900381 | 0.80 | ALDH1A1 (0.49) | PTGER4MAPTTDP1L3MBTL1CYP3A4 | |
| SCHEMBL6921654 | 0.76 | HTR6 (0.49) | HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL4901387 | 0.75 | PTGER4 (0.50) | PTGER4MAPTALDH1A1HPGD | |
| SCHEMBL1149879 | 0.75 | PTGER4 (0.67) | PTGER4CYP1A2ALDH1A1CYP2C19HPGD | |
| SCHEMBL22163073 | 0.72 | PSEN1 (0.47) | ALDH1A1LMNAHPGD | |
| SCHEMBL6920951 | 0.71 | CYP19A1 (0.53) | MAPK1MAPTALDH1A1 | |
| SCHEMBL6921144 | 0.71 | CYP19A1 (0.53) | TDP1ALDH1A1HPGD | |
| SCHEMBL6926400 | 0.71 | HTR1B (0.51) | TDP1CYP1A2ALDH1A1HTR1AADRA1A | |
| SCHEMBL6924418 | 0.71 | HTR1B (0.51) | L3MBTL1CYP1A2CYP3A4LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ARTESIAN THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ARTESIAN THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ARTESIAN THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1833480-A2 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | Artesian Therapeutics, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006060122-A9 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | ARTESIAN THERAPEUTICS INC (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006060122-A9 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | ARTESIAN THERAPEUTICS INC (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006060122-A2 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | ARTESIAN THERAPEUTICS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006060122-A2 | CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST BETA-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE | ARTESIAN THERAPEUTICS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255134-A1 | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase | ADRB3, PDE3A, ADRB1 | MAPK1 1633/4885PTGER4 286/4885MAPT 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.